Browse > Article
http://dx.doi.org/10.1016/j.jgr.2016.12.003

Global analysis of ginsenoside Rg1 protective effects in β-amyloid-treated neuronal cells  

Shim, Ji Seon (Department of Physiology, School of Medicine, Kyung Hee University)
Song, Min-Young (Department of Physiology, School of Medicine, Kyung Hee University)
Yim, Sung-Vin (Department of Clinical Pharmacology, School of Medicine, Kyung Hee University)
Lee, Seung-Eun (Department of Herbal Crop Research, National Institute of Horticultural & Herbal Science)
Park, Kang-Sik (Department of Physiology, School of Medicine, Kyung Hee University)
Publication Information
Journal of Ginseng Research / v.41, no.4, 2017 , pp. 566-571 More about this Journal
Abstract
Background: A number of reports have described the protective effects of ginsenoside Rg1 (Rg1) in Alzheimer's disease (AD). However, the protective mechanisms of Rg1 in AD remain elusive. Methods: To investigate the potential mechanisms of Rg1 in ${\beta}$-amyloid peptide-treated SH-SY5Y cells, a comparative proteomic analysis was performed using stable isotope labeling with amino acids in cell culture combined with nano-LC-MS/MS. Results: We identified a total of 1,149 proteins in three independent experiments. Forty-nine proteins were significantly altered by Rg1 after exposure of the cells to ${\beta}$-amyloid peptides. The protein interaction network analysis showed that these altered proteins were clustered in ribosomal proteins, mitochondria, the actin cytoskeleton, and splicing proteins. Among these proteins, mitochondrial proteins containing HSD17B10, AARS2, TOMM40, VDAC1, COX5A, and NDUFA4 were associated with mitochondrial dysfunction in the pathogenesis of AD. Conclusion: Our results suggest that mitochondrial proteins may be related to the protective mechanisms of Rg1 in AD.
Keywords
Alzheimer's disease; ginsenoside Rg1; mitochondria; proteomics; SILAC;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Giovannelli L, Scali C, Faussone-Pellegrini MS, Pepeu G, Casamenti F. Long-term changes in the aggregation state and toxic effects of beta-amyloid injected into the rat brain. Neuroscience 1998;87:349-57.   DOI
2 Giovannelli L, Casamenti F, Scali C, Bartolini L, Pepeu G. Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. Neuroscience 1995;66:781-92.   DOI
3 Hwang JY, Shim JS, Song MY, Yim SV, Lee SE, Park KS. Proteomic analysis reveals that the protective effects of ginsenoside Rb1 are associated with the actin cytoskeleton in beta-amyloid-treated neuronal cells. J Ginseng Res 2016;40:278-84.   DOI
4 Choi JW, Song MY, Park KS. Quantitative proteomic analysis reveals mitochondrial protein changes in MPP(+)-induced neuronal cells. Mol Biosyst 2014;10:1940-7.   DOI
5 Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011;39:D561-8.   DOI
6 Shearman MS, Ragan CI, Iversen LL. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc Natl Acad Sci U S A 1994;91:1470-4.   DOI
7 Saw CL, Yang AY, Cheng DC, Boyanapalli SS, Su ZY, Khor TO, Gao S, Wang J, Jiang ZH, Kong AN. Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations. Chem Res Toxicol 2012;25:1574-80.   DOI
8 Gottschalk WK, Lutz MW, He YT, Saunders AM, Burns DK, Roses AD, Chiba-Falek O. The broad impact of TOM40 on neurodegenerative diseases in aging. J Parkinsons Dis Alzheimers Dis 2014. http://dx.doi.org/10.13188/2376-922X.1000003.   DOI
9 Lee TS, Goh L, Chong MS, Chua SM, Chen GB, Feng L, Lim WS, Chan M, Ng TP, Krishnan KR. Downregulation of TOMM40 expression in the blood of Alzheimer disease subjects compared with matched controls. J Psychiatr Res 2012;46:828-30.   DOI
10 Goh LK, Lim WS, Teo S, Vijayaraghavan A, Chan M, Tay L, Ng TP, Tan CH, Lee TS, Chong MS. TOMM40 alterations in Alzheimer's disease over a 2-year follow-up period. J Alzheimers Dis 2015;44:57-61.   DOI
11 Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 2012;21:5131-46.   DOI
12 Yang SY, He XY, Schulz H. 3-Hydroxyacyl-CoA dehydrogenase and short chain 3-hydroxyacyl-CoA dehydrogenase in human health and disease. FEBS J 2005;272:4874-83.   DOI
13 Reddy PH. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2013;1832:67-75.   DOI
14 Ren R, Zhang Y, Li B, Wu Y, Li B. Effect of beta-amyloid (25-35) on mitochondrial function and expression of mitochondrial permeability transition pore proteins in rat hippocampal neurons. J Cell Biochem 2011;112:1450-7.   DOI
15 Hernandez-Zimbron LF, Luna-Munoz J, Mena R, Vazquez-Ramirez R, Kubli-Garfias C, Cribbs DH, Manoutcharian K, Gevorkian G. Amyloid-beta peptide binds to cytochrome C oxidase subunit 1. PLoS One 2012;7:e42344.   DOI
16 Sekar S, McDonald J, Cuyugan L, Aldrich J, Kurdoglu A, Adkins J, Serrano G, Beach TG, Craig DW, Valla J, et al. Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging 2015;36:583-91.   DOI
17 Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-84.   DOI
18 Correa MS, Vedovelli K, Giacobbo BL, de Souza CE, Ferrari P, de Lima Argimon II, Walz JC, Kapczinski F, Bromberg E. Psychophysiological correlates of cognitive deficits in family caregivers of patients with Alzheimer disease. Neuroscience 2015;286:371-82.   DOI
19 Mucke L. Neuroscience: Alzheimer's disease. Nature 2009;461:895-7.   DOI
20 Piaceri I, Rinnoci V, Bagnoli S, Failli Y, Sorbi S. Mitochondria and Alzheimer's disease. J Neurol Sci 2012;322:31-4.   DOI
21 Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-9.   DOI
22 Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-41.   DOI
23 Pinho CM, Teixeira PF, Glaser E. Mitochondrial import and degradation of amyloid-beta peptide. Biochim Biophys Acta 2014;1837:1069-74.   DOI
24 Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS. The toxicity in vitro of beta-amyloid protein. Biochem J 1995;311:1-16.   DOI
25 Shen L, Zhang J. NMDA receptor and iNOS are involved in the effects of ginsenoside Rg1 on hippocampal neurogenesis in ischemic gerbils. Neurol Res 2007;29:270-3.   DOI
26 Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008;14:45-53.   DOI
27 Cho IH. Effects of Panax ginseng in neurodegenerative diseases. J Ginseng Res 2012;36:342-53.   DOI
28 Chen XC, Zhu YG, Zhu LA, Huang C, Chen Y, Chen LM, Fang F, Zhou YC, Zhao CH. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol 2003;473:1-7.   DOI
29 Im DS, Nah SY. Yin and Yang of ginseng pharmacology: ginsenosides vs gintonin. Acta Pharmacol Sin 2013;34:1367-73.   DOI
30 Li N, Zhou L, Li W, Liu Y, Wang J, He P. Protective effects of ginsenosides Rg1 and Rb1 on an Alzheimer's disease mouse model: a metabolomics study. J Chromatogr B Analyt Technol Biomed Life Sci 2015;985:54-61.   DOI
31 Wang YH, Du GH. Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res 2009;11:604-12.   DOI